Advertisement

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

  • Rosie Cornish
  • Anne Cathrine Staff
  • Andy Boyd
  • Debbie A. Lawlor
  • Steinar Tretli
  • Gary Bradwin
  • Thomas F. McElrath
  • Marianne Hyer
  • Robert N. Hoover
  • Rebecca Troisi
Original paper
  • 23 Downloads

Abstract

Purpose

Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors.

Methods

We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n = 254 cases and 374 controls), placental growth factor (PlGF, n = 252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n = 118 and 240) and steroid hormone concentrations (ALSPAC only, n = 173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother’s birth year, serum/plasma, blood collection timing) and gestational age.

Results

Breast cancer ORs (95% CI) were 0.85 (0.51–1.43) for estradiol, 0.86 (0.67–1.09) for testosterone, 0.89 (0.71–1.13) for androstenedione, 0.97 (0.71–1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78–1.27) for PlGF and 1.91 (1.00–3.65 ALSPAC) and 0.94 (0.73–1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis.

Conclusion

These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.

Keywords

Pregnancy Estrogens Androgens Hormones Angiogenic factors Breast cancer ALSPAC MoBa 

Notes

Acknowledgements

We are extremely grateful to all the ALSPAC and MoBa families who take part in these ongoing studies, the midwives for their help in recruiting them, and the entire study teams in the UK and Norway (including interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses). This publication is the work of the authors who will serve as guarantors for the contents of this paper. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. AB’s and RC’s contributions were funded by the Wellcome Trust (Grant ref: WT086118/Z/08/Z). DAL’s contribution to this paper was supported by the NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. DAL works in a Unit that receives support from the University of Bristol and the UK Medical Research Council (MC_UU_1201/5) and she is a NIHR Senior Investigator (NF-SI-0166-10196). The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, NIH/NIEHS (contract no N01-ES-75558), NIH/NINDS (grant no.1 UO1 NS 047537- 01 and grant no.2 UO1 NS 047537-06A1). ACS’s contribution to the paper was supported by Oslo University Hospital, the Division of Obstetrics and Gynecology. The National Cancer Institute provided intramural funds to perform the assays and to support RT’s and MH’s research time. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this paper are those of the authors and not necessarily those of the UK Medical Research Council, National Health Service, National Institute for Health Research, or Department of Health, or any other funder listed above.

Compliance with ethical standards

Conflict of interest

DAL has received support from Roche Diagnostics, Medtronic, UK, EU, and US government funding bodies and UK charities for research unrelated to that presented in this paper. All other authors declare no conflict of interest regarding support for the work under consideration, or for other projects, either financial or in kind from any third party, company or organisation whose finances or reputation may be affected by the publication of the work; any recent, existing or planned employment relationship or consultancy (whether paid or unpaid) any of the authors has with an organisation whose finances or reputation may be affected by the publication of the work; or any direct financial interest any of the authors or their spouses, parents or children has (personal shareholdings, consultancies, patents or patent applications) whose value could be affected by the publication.

Informed consent

The current analysis makes secondary use of pre-existing data from ALSPAC and MoBa participants who provided written informed consent.

Research involving human participants

Ethical approval in ALSPAC was obtained from the ALSPAC Ethics and Law Committee and NHS Research Ethics Committees. Access and use of the linked ALSPAC cancer registry information was restricted to AB and RC who are ONS Accredited Researchers operating within the ONS ‘Safe Research’ framework. MoBa has a license from the Norwegian Data Inspectorate (01-4325) and approval from the Regional Committee for Medical Research Ethics (REK), Southern Norway (S-97045, S-95113). The angiogenic factor study received approval from REK, South-Eastern Norway (S-08541a) and a license from the Norwegian Data Inspectorate (08/01126-4). At the U.S. National Cancer Institute, the project was reviewed by the Office of Human Subjects Research and exempted from institutional review board approval on the basis that the analysis was performed in the U.K. using de-identified data.

Supplementary material

10552_2018_1100_MOESM1_ESM.docx (141 kb)
Supplementary material 1 (DOCX 140 KB)

References

  1. 1.
    Medina D (2005) Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12:483–495CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281–291CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Key T, Appleby P, Barnes I, Reeves G, Endogenous, Hormones & Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Richardson BE, Hulka BS, Peck JL, Hughes CL, van den Berg BJ, Christianson RE, Calvin JA (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Melbye M, Wohlfahrt J, Lei U, Nørgaard-Pedersen B, Mouridsen HT, Lambe M, Michels KB (2000) Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 92:1001–1005CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE (2002) Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev 11:361–368PubMedPubMedCentralGoogle Scholar
  7. 7.
    Lukanova A, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K, Wulff M, Arslan AA, Afanasyeva Y, Johansson R, Lenner P, Hallmans G et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 15:2489–2493CrossRefGoogle Scholar
  8. 8.
    Lukanova A, Andersson R, Wulff M, Zeleniuch-Jacquotte A, Grankvist K, Dossus L, Afanasyeva Y, Johansson R, Arslan AA, Lenner P et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study. Am J Epidemiol 168:1284–1291CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, Husing A, Kaaks R, Koskela P, Grankvist K et al (2012) Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer 130:910–920CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Vatten LJ, Romundstad PR, Jenum PA, Eskild A (2009) Angiogenic balance in pregnancy and subsequent breast cancer risk and survival: a population study. Cancer Epidemiol Biomark Prev 18:2074–2078CrossRefGoogle Scholar
  11. 11.
    Jeffreys M, Northstone K, Holly J, Emmett P, Gunnell D (2011) Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case-control study. Cancer Causes Control 22:945–953CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Toniolo P, Grankvist K, Wulff M, Chen T, Johansson R, Schock H, Lenner P, Hallmans G, Lehtinen M, Kaaks R et al (2010) Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. Cancer Res 70:6779–6786CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Toriola AT, Lundin E, Schock H, Grankvist K, Pukkala E, Chen T, Zeleniuch-Jacquotte A, Toniolo P, Lehtinen M, Surcel HM et al (2011) Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 20:1798–1801CrossRefGoogle Scholar
  14. 14.
    Toriola AT, Tolockiene E, Schock H, Surcel HM, Zeleniuch-Jacquotte A, Wadell G, Toniolo P, Lundin E, Grankvist K, Lukanova A (2014) Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer. Future Oncol 10:377–384CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Grankvist K et al (2014) Early pregnancy sex steroids and maternal breast cancer: a nested case-control study. Cancer Res 74:6958–6967CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Fortner RT, Tolockiene E, Schock H, Oda H, Lakso H, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K et al (2017) Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden maternity cohort. Breast Cancer Res 19:82CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Cohn BA, Cirillo PM, Hopper BR, Siiteri PK (2017) Third trimester estrogens and maternal breast cancer: prospective evidence. J Clin Endocrinol Metab 102:3739–3748CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Troisi R, Weiss HA, Hoover RN, Potischman N, Swanson CA, Brogan DR, Coates RJ, Gammon MD, Malone KE, Daling JR et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R (2002) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 87:971–973CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005) Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57:1R–7RCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Aagaard-Tillery KM, Stoddard GJ, Holmgren C, Lacoursiere DY, Fraser A, Mineau GP, Varner MW (2006) Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 195:691–699CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 199:653.e1–653.e10CrossRefGoogle Scholar
  24. 24.
    Redman CW, Staff AC (2015) Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 213:S9.e1–S9.e11CrossRefGoogle Scholar
  25. 25.
    Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G (2013) Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 42:111–127CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A et al (2013) Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 42:97–110CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Hoiseth G, Knudsen GP et al (2016) Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 45:382–388CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C et al (2015) Data processing and analytic support in the PLCO cancer screening trial. Rev Recent Clin Trials 10:233–237CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Troisi R, Ganmaa D, dos Santos Silva I, Davaalkham D, Rosenberg PS, Rich-Edwards J, Frasier L, Houghton L, Janes C, Stanczyk F et al (2014) The role of hormones in the differences in the incidence of breast cancer between Mongolia and the United Kingdom. PLoS ONE 9:e114455CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Paltiel L, Haugan A, Skjerden T, Harbak K, Bækken S, Stensrud NK, Knudsen GP, Magnus P (2014) The biobank of the Norwegian Mother and Child Cohort Study—present status. Nor J Epidemiol 24:29–35CrossRefGoogle Scholar
  31. 31.
    Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28:964–974CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Korpela J et al (2017) Human chorionic gonadotropin does not correlate with risk for maternal breast cancer: results from the finnish maternity cohort. Cancer Res 77:134–141CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 6:25998CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso H-Å, Idahl A, Lehtinen M, Surcel H-M, Fortner RT (2016) Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 16:146CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Neville MC, McFadden TB, Forsyth I (2002) Hormonal regulation of mammary differentiation and milk secretion. J Mamm Gland Biol Neoplasia 7:49–66CrossRefGoogle Scholar
  37. 37.
    Pepe G, Albrecht E (2008) Steroid endocrinology of pregnancy. Glob Libr Women’s Med. ISSN: 1756–2228.  https://doi.org/10.3843/GLOWM.10311
  38. 38.
    Fuhrman BJ, Xu X, Falk RT, Hankinson SE, Veenstra TD, Keefer LK, Ziegler RG (2010) Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies. Int J Biol Mark 25:185–194CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2018

Authors and Affiliations

  • Rosie Cornish
    • 1
  • Anne Cathrine Staff
    • 2
  • Andy Boyd
    • 1
  • Debbie A. Lawlor
    • 1
    • 3
    • 4
  • Steinar Tretli
    • 5
  • Gary Bradwin
    • 6
  • Thomas F. McElrath
    • 7
  • Marianne Hyer
    • 8
  • Robert N. Hoover
    • 9
  • Rebecca Troisi
    • 9
  1. 1.Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
  2. 2.Division of Obstetrics and GynecologyOslo University Hospital and University of OsloOsloNorway
  3. 3.MRC Integrative Epidemiology Unit at the University of BristolBristolUK
  4. 4.NIHR Bristol Biomedical Research CentreUniversity of BristolBristolUK
  5. 5.Cancer Registry of NorwayInstitute of Population-Based Cancer ResearchOsloNorway
  6. 6.Clinical and Epidemiologic Research LaboratoryBoston Children’s HospitalBostonUSA
  7. 7.Department of Obstetrics and Gynecology, Harvard Medical SchoolBrigham and Women’s HospitalBostonUSA
  8. 8.Information Management ServicesRockvilleUSA
  9. 9.Epidemiology and Biostatistics Program, Division of Epidemiology and GeneticsNational Cancer InstituteRockvilleUSA

Personalised recommendations